Cognitive behavioral therapy for bipolar disorder: patient-level participation barriers and ketogenic metabolic therapy as a candidate adjunct.

This conceptual analysis synthesizes patient-level participation barriers described in the bipolar disorder CBT literature and considers ketogenic metabolic therapy (KMT) as a candidate adjunct within a delivery-focused framework. CBT is an evidence-based adjunctive psychotherapy for bipolar disorder, but its clinical value depends on whether patients initiate treatment, sustain session continuity, and complete between-session practice that supports skill use in daily life. In routine care, psychotherapy uptake remains limited, discontinuation can occur early, and patient-level barriers can constrain delivered dose. Early clinical evidence for KMT in bipolar disorder remains preliminary and does not support conclusions regarding disorder-level efficacy or comparative effectiveness. Case reports, retrospective analyses, and pilot trials describe KMT-associated change in domains that overlap with capacity for CBT participation, including mood stability, sleep, energy, anxiety, cognition, and functioning. To date, no studies have directly tested whether KMT improves CBT participation outcomes (initiation, continuity, or between-session practice) in bipolar disorder. This article presents a participation-capacity framework that evaluates KMT as an adjunct to guideline-consistent care and operationalizes research priorities for measuring participation, feasibility, and fidelity across psychotherapy dose, between-session practice, and verified ketosis, rather than symptom change alone. The model specifies sequential decision points for introducing KMT before CBT when participation capacity limits initiation or early continuity, or after participation barriers emerge. CBT is initiated or resumed when pre-specified participation-readiness indicators suggest that an adequate CBT dose can be delivered.